ASMB Key Statistics, Chart & Performance
The current stock price of ASMB is 31.74 USD. In the past month the price decreased by -11.51%. In the past year, price increased by 103.2%.
ASMB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B |
Related stock screener links
About ASMB
Company Profile
Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. The company is headquartered in South San Francisco, California and currently employs 73 full-time employees. The company went IPO on 2010-12-17. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. The company is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).
Company Info
ASSEMBLY BIOSCIENCES INC
Two Tower Place, 7Th Floor
South San Francisco CALIFORNIA 94080 US
CEO: John G. McHutchison
Employees: 73
Phone: 18334094583
ASSEMBLY BIOSCIENCES INC / ASMB FAQ
What does ASSEMBLY BIOSCIENCES INC do?
Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. The company is headquartered in South San Francisco, California and currently employs 73 full-time employees. The company went IPO on 2010-12-17. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. The company is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).
Can you provide the latest stock price for ASSEMBLY BIOSCIENCES INC?
The current stock price of ASMB is 31.74 USD. The price increased by 0.57% in the last trading session.
Does ASSEMBLY BIOSCIENCES INC pay dividends?
ASMB does not pay a dividend.
How is the ChartMill rating for ASSEMBLY BIOSCIENCES INC?
ASMB has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the ownership details for ASMB stock?
You can find the ownership structure of ASSEMBLY BIOSCIENCES INC (ASMB) on the Ownership tab.
Can you provide the short interest for ASMB stock?
The outstanding short interest for ASSEMBLY BIOSCIENCES INC (ASMB) is 13.51% of its float.
ASMB Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to ASMB. When comparing the yearly performance of all stocks, ASMB is one of the better performing stocks in the market, outperforming 94.05% of all stocks.
ASMB Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ASMB. The financial health of ASMB is average, but there are quite some concerns on its profitability.
ASMB Financial Highlights
Over the last trailing twelve months ASMB reported a non-GAAP Earnings per Share(EPS) of -4.79. The EPS increased by 34.38% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -16.06% | ||
| ROE | -21.1% | ||
| Debt/Equity | 0 |
ASMB Forecast & Estimates
10 analysts have analysed ASMB and the average price target is 48.71 USD. This implies a price increase of 53.45% is expected in the next year compared to the current price of 31.74.
For the next year, analysts expect an EPS growth of 45.91% and a revenue growth 38.92% for ASMB